Cancer

GTG Signs Precision Medicine Pilot with Australia’s Largest Private Hospital Network

GeneType and Gold Coast Hospital Simon Morriss - Genetic Technologies Ltd CEO and Michelle Ferrari Cestari - Gold Coast Hospital…

1 year ago

Beyond Cancer™ to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting

Abstract titles to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting were released publicly today at…

1 year ago

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Presentations to highlight new nonclinical data on product candidates, new technologies, innovations designed to shorten TIL manufacturing and clinical trials…

1 year ago

SIRPant Immunotherapeutics to Present Trial in Progress Poster at the Society for Immunotherapy of Cancer 38th Annual Meeting

HUMMELSTOWN, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics Inc, a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based…

1 year ago

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Six abstracts, spanning Werewolf’s PREDATOR™ platform and INDUKINE™ pipeline, accepted for poster presentations at SITC annual meetingCompany to present interim…

1 year ago

Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023

Qualigen Therapeutics, Inc. Figure 1A Qualigen Therapeutics, Inc. Figure 1B Qualigen Therapeutics, Inc. Table 1Two posters include data on potential clinical biomarkers…

1 year ago

Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate

Updated results from the BCMA/CD19 dual-targeted GC012F, including longer-term follow-up and three additional patients, presented at the International Myeloma Society…

1 year ago

Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology

Clinical trial evaluating the Company’s novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94% with specificity of 97% and…

1 year ago

Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein

Planegg/Martinsried, September 27, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the…

1 year ago